Company intelligence
Hematogenix
About Hematogenix
Hematogenix, a global cancer-focused life science company serving the pharmaceutical & biotechnology industry as well as community physicians. With passionate scientists and board-certified clinical and anatomic pathologists and hematopathologists from around the world, Hematogenix offers an array of biomarker development and testing services navigating the complexities of human diseases and clinical trials. Our global team of scientists provides reference laboratory services at our facilities around the globe: in the US, Europe, China, and Asia-Pacific. We are uniquely equipped to help clients accelerate cancer research and drug development efforts at these globally connected facilities. Hematogenix provides a complete menu of services such as Flow Cytometry, Molecular Genetics, Next Generation Sequencing (NGS), Histology / Immunohistochemistry (IHC), Cytogenetics / FISH, Pathology, Digital Pathology and Image Analysis. Our test menu reflects our commitment to utilizing the most advanced techniques to enhance patient care. We provide customized services ranging from the initial stages of research to development, and extending all the way to the implementation of targeted therapies in the clinical setting. * CAP – Accredited * CLIA – Certified * GCP – Compliant
Verified activity
Signals from Hematogenix
2 published signals
Legal & Regulatory
Hematogenix UK has successfully completed its latest College of American Pathologists (CAP) inspection with NO DEFICIENCIES cited.
Reported by Hematogenix
Products & Services
Hematogenix launched the cfDNA Comprehensive Genomic Profiling Panel, a single plasma-based assay that simultaneously detects multiple biomarker classes including SNVs, Indels, CNVs, MSI, TMB, HRR gene alterations, and DNA-level fusions.
Reported by Hematogenix